TNX-801 (live virus vaccine for percutaneous (scarification) administration) is a potential smallpox-preventing vaccine based on a live synthetic version of horsepox virus
, currently in the pre-IND application stage.
"The synthesis of horsepox virus
takes the world one step closer to the reemergence of smallpox as a threat to global health security."
Researchers from the University of Alberta produced an infectious horsepox virus
, which they synthetically reconstructed using a published genome sequence and DNA fragments manufactured entirely by chemical methods.
Tonix Pharmaceuticals Holding announced the publication of research describing the successful synthesis and characterization of a potential smallpox-preventing vaccine based on horsepox virus
. The research was conducted in conjunction with scientists from the University of Alberta, a leading Canadian research university.
As an example, Science reported in July 2017 that a team of Canadian researchers synthesized the horsepox virus
, a relative of smallpox, from genetic pieces ordered through the mail.
We compared molecular sequence data from 3 genes and a variable region of the poxvirus genome (Table 1) among BRZ-VACV isolates, available vaccine strains related to those used during the eradication campaign in Brazil, and other VACVs isolated from domestic animals (including endemic buffalopox virus in India [15-17] and horsepox virus
[HSPV] from Asia ).
TNX-801 (live horsepox virus
vaccine for percutaneous (scarification) administration) is a novel, live virus vaccine grown in cell culture that is a potential smallpox-preventing vaccine currently in the pre-IND application stage of development.